Firms are taking big bets on the technology’s potential to transform consulting work. But they shouldn’t lose sight of the unique value humans can bring.
Academic rigor, journalistic flair
Articles on BCG
Displaying all articles
Less than half of the children aged 0-14 who have TB are diagnosed – so they never even start treatment.
Manufacturers and health systems have shown that vaccines can be quickly and effectively deployed when accompanied by keen political and financial commitments.
BCG remains the only widely available vaccine for TB. Yet the development of a COVID-19 vaccine over the last year shows that there is capacity to rapidly create new vaccines.
Until vaccines that are capable of protecting all populations against TB are developed, treatment is the best option to preventing infection.
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
Vaccines for other diseases are being examined for their protective effects against coronavirus.
Vaccines have ‘non-specific effects’ that have the potential to save millions of lives.
Top contributors
-
Professor of Global Health, Danish Institute for Advanced Study, University of Southern Denmark
-
Lead Senior Scientist, Aurum Institute
-
Senior Research Fellow, James Cook University
-
Head of the Centre of Excellence for Biomedical TB Research, University of the Witwatersrand
-
Socio-behavioural Scientist and Senior Researcher, Stellenbosch University
-
Assistant Professor in Health Economics, London School of Hygiene & Tropical Medicine
-
Clinical Research Fellow in Viral Immunology and Veterinary Surgeon, University of Cambridge
-
ARC DECRA Fellow / Lecturer in Business Information Systems, The University of Queensland
-
Assistant Professor, Infectious Disease Epidemiology , London School of Hygiene & Tropical Medicine
